Titre : Troubles anxieux

Troubles anxieux : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Troubles anxieux : Questions médicales les plus fréquentes", "headline": "Troubles anxieux : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Troubles anxieux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-03", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Troubles anxieux" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles mentaux", "url": "https://questionsmedicales.fr/mesh/D001523", "about": { "@type": "MedicalCondition", "name": "Troubles mentaux", "code": { "@type": "MedicalCode", "code": "D001523", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Asthénie neurocirculatoire", "alternateName": "Neurocirculatory Asthenia", "url": "https://questionsmedicales.fr/mesh/D009449", "about": { "@type": "MedicalCondition", "name": "Asthénie neurocirculatoire", "code": { "@type": "MedicalCode", "code": "D009449", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.500" } } }, { "@type": "MedicalWebPage", "name": "Trouble obsessionnel compulsif", "alternateName": "Obsessive-Compulsive Disorder", "url": "https://questionsmedicales.fr/mesh/D009771", "about": { "@type": "MedicalCondition", "name": "Trouble obsessionnel compulsif", "code": { "@type": "MedicalCode", "code": "D009771", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.600" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Syllogomanie", "alternateName": "Hoarding Disorder", "url": "https://questionsmedicales.fr/mesh/D000067836", "about": { "@type": "MedicalCondition", "name": "Syllogomanie", "code": { "@type": "MedicalCode", "code": "D000067836", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.600.250" } } } ] }, { "@type": "MedicalWebPage", "name": "Trouble panique", "alternateName": "Panic Disorder", "url": "https://questionsmedicales.fr/mesh/D016584", "about": { "@type": "MedicalCondition", "name": "Trouble panique", "code": { "@type": "MedicalCode", "code": "D016584", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.700" } } }, { "@type": "MedicalWebPage", "name": "Troubles phobiques", "alternateName": "Phobic Disorders", "url": "https://questionsmedicales.fr/mesh/D010698", "about": { "@type": "MedicalCondition", "name": "Troubles phobiques", "code": { "@type": "MedicalCode", "code": "D010698", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.725" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Agoraphobie", "alternateName": "Agoraphobia", "url": "https://questionsmedicales.fr/mesh/D000379", "about": { "@type": "MedicalCondition", "name": "Agoraphobie", "code": { "@type": "MedicalCode", "code": "D000379", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.725.250" } } }, { "@type": "MedicalWebPage", "name": "Kinésiophobie", "alternateName": "Kinesiophobia", "url": "https://questionsmedicales.fr/mesh/D000092442", "about": { "@type": "MedicalCondition", "name": "Kinésiophobie", "code": { "@type": "MedicalCode", "code": "D000092442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.725.375" } } }, { "@type": "MedicalWebPage", "name": "Phobie sociale", "alternateName": "Phobia, Social", "url": "https://questionsmedicales.fr/mesh/D000072861", "about": { "@type": "MedicalCondition", "name": "Phobie sociale", "code": { "@type": "MedicalCode", "code": "D000072861", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.080.725.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Troubles anxieux", "alternateName": "Anxiety Disorders", "code": { "@type": "MedicalCode", "code": "D001008", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jeffrey R Strawn", "url": "https://questionsmedicales.fr/author/Jeffrey%20R%20Strawn", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry & Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, OH, USA." } }, { "@type": "Person", "name": "Rosa Joseph", "url": "https://questionsmedicales.fr/author/Rosa%20Joseph", "affiliation": { "@type": "Organization", "name": "Department of Family Medicine and Rural Health - Florida State University College of Medicine, 1115 West Call St, Tallahassee, FL 32306." } }, { "@type": "Person", "name": "Ashley Falk", "url": "https://questionsmedicales.fr/author/Ashley%20Falk", "affiliation": { "@type": "Organization", "name": "Department of Family Medicine and Rural Health - Florida State University College of Medicine, 1115 West Call St, Tallahassee, FL 32306." } }, { "@type": "Person", "name": "Shannon Smith", "url": "https://questionsmedicales.fr/author/Shannon%20Smith", "affiliation": { "@type": "Organization", "name": "Florida State University College of Medicine Family Medicine Residency Program at BayCare Health System - Winter Haven, 1201 First St. S Suite 100A, Winter Haven, FL 33880." } }, { "@type": "Person", "name": "Ashley Wilk", "url": "https://questionsmedicales.fr/author/Ashley%20Wilk", "affiliation": { "@type": "Organization", "name": "Department of Family Medicine and Rural Health - Florida State University College of Medicine, 1115 West Call St, Tallahassee, FL 32306." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction.", "datePublished": "2023-04-27", "url": "https://questionsmedicales.fr/article/37105991", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-023-37988-7" } }, { "@type": "ScholarlyArticle", "name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37072660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02510-4" } }, { "@type": "ScholarlyArticle", "name": "Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.", "datePublished": "2023-02-07", "url": "https://questionsmedicales.fr/article/36750531", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02438-9" } }, { "@type": "ScholarlyArticle", "name": "Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.", "datePublished": "2024-08-12", "url": "https://questionsmedicales.fr/article/39133885", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1212/NXI.0000000000200293" } }, { "@type": "ScholarlyArticle", "name": "COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY AFTER KIDNEY TRANSPLANT: SHOULD TREATMENT WITH C5 INHIBITOR BE LIFELONG?", "datePublished": "2024-04-14", "url": "https://questionsmedicales.fr/article/38615653", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000538826" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Troubles mentaux", "item": "https://questionsmedicales.fr/mesh/D001523" }, { "@type": "ListItem", "position": 3, "name": "Troubles anxieux", "item": "https://questionsmedicales.fr/mesh/D001008" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Troubles anxieux - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Troubles anxieux", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Troubles anxieux", "description": "Comment diagnostique-t-on un trouble anxieux ?\nQuels critères sont utilisés pour le diagnostic ?\nLes tests sont-ils nécessaires pour le diagnostic ?\nQui peut diagnostiquer un trouble anxieux ?\nLes antécédents familiaux influencent-ils le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D001008?mesh_terms=Complement+C5&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Troubles anxieux", "description": "Quels sont les symptômes courants des troubles anxieux ?\nComment l'anxiété se manifeste-t-elle physiquement ?\nLes troubles de l'humeur sont-ils liés aux troubles anxieux ?\nLes symptômes varient-ils selon les types de troubles anxieux ?\nL'anxiété peut-elle affecter la concentration ?", "url": "https://questionsmedicales.fr/mesh/D001008?mesh_terms=Complement+C5&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Troubles anxieux", "description": "Peut-on prévenir les troubles anxieux ?\nQuel rôle joue le mode de vie dans la prévention ?\nLa gestion du stress est-elle importante ?\nLes réseaux sociaux influencent-ils l'anxiété ?\nLes techniques de pleine conscience aident-elles ?", "url": "https://questionsmedicales.fr/mesh/D001008?mesh_terms=Complement+C5&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Troubles anxieux", "description": "Quels traitements sont disponibles pour les troubles anxieux ?\nLes médicaments sont-ils toujours nécessaires ?\nLa thérapie de groupe est-elle efficace ?\nLes techniques de relaxation aident-elles ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D001008?mesh_terms=Complement+C5&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Troubles anxieux", "description": "Quels sont les risques de complications liées aux troubles anxieux ?\nLes troubles anxieux peuvent-ils affecter la santé physique ?\nComment l'anxiété impacte-t-elle la vie sociale ?\nLes troubles anxieux augmentent-ils le risque suicidaire ?\nLes complications peuvent-elles aggraver l'anxiété ?", "url": "https://questionsmedicales.fr/mesh/D001008?mesh_terms=Complement+C5&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Troubles anxieux", "description": "Quels sont les principaux facteurs de risque des troubles anxieux ?\nLe sexe influence-t-il le risque d'anxiété ?\nL'âge joue-t-il un rôle dans l'anxiété ?\nLes antécédents de traumatismes augmentent-ils le risque ?\nLe stress chronique est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D001008?mesh_terms=Complement+C5&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on un trouble anxieux ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation des symptômes et l'exclusion d'autres troubles." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la durée des symptômes et leur impact sur la vie quotidienne." } }, { "@type": "Question", "name": "Les tests sont-ils nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des tests peuvent être utilisés pour exclure d'autres conditions, mais pas pour diagnostiquer." } }, { "@type": "Question", "name": "Qui peut diagnostiquer un trouble anxieux ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel de santé mentale, comme un psychiatre ou un psychologue, peut diagnostiquer." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents familiaux peuvent jouer un rôle dans le diagnostic et la prédisposition." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des troubles anxieux ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent l'inquiétude excessive, l'agitation, et des troubles du sommeil." } }, { "@type": "Question", "name": "Comment l'anxiété se manifeste-t-elle physiquement ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des palpitations, des tremblements, et des douleurs musculaires." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils liés aux troubles anxieux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent coexister, rendant le diagnostic et le traitement plus complexes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les types de troubles anxieux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type de trouble anxieux présente des symptômes spécifiques et variés." } }, { "@type": "Question", "name": "L'anxiété peut-elle affecter la concentration ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'anxiété peut entraîner des difficultés de concentration et de mémoire." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles anxieux ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Bien que la prévention complète soit difficile, des stratégies peuvent réduire le risque." } }, { "@type": "Question", "name": "Quel rôle joue le mode de vie dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant exercice et alimentation équilibrée, peut aider." } }, { "@type": "Question", "name": "La gestion du stress est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, apprendre à gérer le stress peut réduire le risque de développer des troubles anxieux." } }, { "@type": "Question", "name": "Les réseaux sociaux influencent-ils l'anxiété ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une utilisation excessive des réseaux sociaux peut augmenter l'anxiété chez certains individus." } }, { "@type": "Question", "name": "Les techniques de pleine conscience aident-elles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la pleine conscience peut aider à réduire l'anxiété et améliorer le bien-être général." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les troubles anxieux ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie cognitivo-comportementale et les médicaments." } }, { "@type": "Question", "name": "Les médicaments sont-ils toujours nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent bénéficier uniquement de la thérapie sans médicaments." } }, { "@type": "Question", "name": "La thérapie de groupe est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie de groupe peut offrir un soutien et des stratégies de gestion de l'anxiété." } }, { "@type": "Question", "name": "Les techniques de relaxation aident-elles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme la méditation et la respiration profonde peuvent réduire l'anxiété." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés aux besoins spécifiques de chaque patient." } }, { "@type": "Question", "name": "Quels sont les risques de complications liées aux troubles anxieux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure la dépression, l'abus de substances et des troubles physiques." } }, { "@type": "Question", "name": "Les troubles anxieux peuvent-ils affecter la santé physique ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'anxiété chronique peut entraîner des problèmes de santé physique comme des maladies cardiaques." } }, { "@type": "Question", "name": "Comment l'anxiété impacte-t-elle la vie sociale ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner l'isolement social et des difficultés dans les relations interpersonnelles." } }, { "@type": "Question", "name": "Les troubles anxieux augmentent-ils le risque suicidaire ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes souffrant de troubles anxieux ont un risque accru de pensées suicidaires." } }, { "@type": "Question", "name": "Les complications peuvent-elles aggraver l'anxiété ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent créer un cercle vicieux, aggravant les symptômes d'anxiété." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque des troubles anxieux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le stress, et des événements traumatiques." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque d'anxiété ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes sont généralement plus susceptibles de développer des troubles anxieux que les hommes." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans l'anxiété ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles anxieux peuvent survenir à tout âge, mais sont fréquents chez les jeunes adultes." } }, { "@type": "Question", "name": "Les antécédents de traumatismes augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes ayant subi des traumatismes sont plus susceptibles de développer des troubles anxieux." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter la vulnérabilité aux troubles anxieux." } } ] } ] }

Sources (1732 au total)

Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction.

African Trypanosomes have developed elaborate mechanisms to escape the adaptive immune response, but little is known about complement evasion particularly at the early stage of infection. Here we show...

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach... The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re... Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence.... Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ... A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12... After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g... Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH.... ClinicalTrials.gov identifier, NCT04085601....

Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.

In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and comp... CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neuro... CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± ... The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic...

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.

Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizuma... To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormali... Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazar... Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed...

In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.

Several diseases caused by the dysregulation of complement activation can be treated with inhibitors of the complement components C5 and/or C3. However, complement is required for serum bactericidal a... Serum from adults was collected before and after vaccination with the meningococcal serogroup B vaccine 4CMenB and tested for meningococcal killing. Since the B capsular polysaccharide is structurally... While only a few pre-vaccination sera showed SBA against the tested B meningococcal isolates, 4CMenB vaccination induced potent complement-activating IgG titers against isolates expressing a matching ... Compared to the SBA triggered by A,C,W,Y capsule polysaccharide conjugate vaccination, SBA against B meningococci expressing a matching fHbp allele was remarkably resilient against the alternative pat...